×

Presenter

Melinda Gooderham



Presentations by Melinda Gooderham
Dupilumab in Children Aged >6 to <12 years Significantly Improves Severe Atopic Dermatitis: Results From Phase 3 Trial (LIBERTY AD PEDS)
Dupilumab in Children Aged >6 to <12 years Significantly Improves Severe Atopic Dermatitis: Results From Phase 3 Trial (LIBERTY AD PEDS)
Melinda Gooderham, Mark Boguniewicz, Lawrence Sher, Jamie Weisman, Ashish Bansal


No presentations found for today.